Success Stories: A Principal Investigator in Oncology from China Obtains NIW Confirmation Without RFE, Thanks to Our Team’s Effort

Client’s Testimonial:

“Thank you for all your efforts on my I-140 NIW approval.”

On April 13^th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for a Principal Investigator in the Field of Oncology (Approval Notice).

General Field: Oncology

Position at the Time of Case Filing: Principal Investigator

Country of Origin: China

Country of Residence at the Time of Filing: China

Approval Notice Date: April 13^th, 2022

Processing Time: 18 months, 22 days

Case Summary:

“[The client’s] research on detecting gastric cancer early is relevant to improving public health outcomes as a whole. One of the most effective ways to reduce cancer mortality is early detection, which comprises both early diagnosis and screening for certain risk factors which carry a higher risk of causing a person to develop cancer. As one of the most prominent researchers in this area, [the client] has considerably increased awareness of these new tools, strengthening research throughout the scientific community. When this is taken into consideration with the practical value of her research, clearly [the client’s] work is of great value to oncology and the medical field as a whole.”

“[The client] is one of the most prolific researchers working in the area of oncology today. This assertion is evidenced by the success of her research efforts related to leukemia, as well as the direct applications of her work. Supporting [the client’s] research presence in the United States is vital in order to remain a world leader in studying more advanced leukemia treatments.”

As is evident from the above statements the support given to our client in these testimonials is very clear about the merit and significance of her work in the field. Our client hailed from China and needed our help with her NIW (National Interest Waiver) petition. The two passages above are drawn from a longer letter written in her favor by other experts in oncology.

As an expert in the field herself, she has been working in this area for the past 8 years. And we also soon found that her proposed endeavor was to work on applying CRISPR and exosome encapsulation techniques to regulate genes that target leukemia in order to discover novel therapeutic targets for acute lymphoblastic leukemia. We immediately knew that her research was of great importance because it aids in the global fight against cancer. Her research was also directly aligned with the interests of the United States.

We made certain of her NIW victory by also saying that she was academically active and her work has resulted in 15 peer-reviewed journal articles (3 of them first-authored) which have been cited a total of 120 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of oncology. From these citations, it is evident that her peers have recognized the value of her work. Additionally, the National Natural Science Foundation of China provided funding for her work. She has also been invited to conduct reviews for other magazines some 4 times already indicating that she is considered an experienced researcher in the area.

On the other hand, she had 4 letters of recommendation supporting her claims to the NIW category, and thus in spite of her application getting an RFE on reaching the adjudication panel, she received her approval albeit a little delayed.

We are confident that she will continue to be an asset to the country and her work shall prove beneficial for the public in the U.S. We wish her all the best in any future endeavors she may take up ahead.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.